Versatope awarded up to $17.9M to develop a universal influenza vaccine using extracellular bacterial vesicles


Computer-assisted visualization of Versatope influenza vaccine candidate. The influenza proteins assemble into a large molecular complex on the surface of exosome-like membrane vesicles. Copyright 2019 Versatope Therapeutics.

Versatope Therapeutics, Inc., a biotechnology company developing vaccines and therapeutics, announced today that it has been awarded a contract with National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) worth up to $17.9M over five years. The award is through the Broad Agency Announcement (BAA) program to advance Versatope’s universal influenza vaccine candidate.

According to the Centers for Disease Control (CDC), influenza vaccines were 29% effective during the last season due to the emergence of new viral strains. The NIAID contract will support Versatope’s goal of producing an influenza vaccine designed to protect against multiple strains using extracellular bacterial vesicles. NIAID funding will support manufacturing, stability and human clinical studies to demonstrate safety and tolerability in healthy volunteers.

“The support from NIAID will advance Versatope’s goal of developing a novel universal influenza vaccine and creating new biotechnology jobs in Lowell, Massachusetts,” said Christopher Locher, Ph.D., CEO of Versatope Therapeutics, Inc. “This is a big advance for our program toward clinical studies and commercialization.”

Lt. Governor of MassachusettsKaryn Politosaid of the NIAID award, “Versatope Therapeutics and its innovations in the biotech industry is driving economic growth and development for the life sciences in Commonwealth. Through its partnership with the Massachusetts Life Sciences Center, we are pleased that Versatope continues to be an innovator in biopharmaceutical manufacturing.”

Shortly after founding Versatope in 2017, Christopher Locher participated in MassBio’s MassCONNECT biotech entrepreneurship mentorship program. “As a graduate of our MassCONNECT mentorship program, the NIAID funding represents a huge milestone for Versatope Therapeutics as they advance their R&D activities,” said Robert K. Coughlin, President & CEO of MassBio. “We are proud to have Versatope be a part of the Massachusetts life sciences community and look forward to their successes as they advance their cutting-edge vaccine technology for patients worldwide.”

Source – Versatope Therapeutics

Leave a Reply

Your email address will not be published. Required fields are marked *